Study the Level of interlukin-2 During and after Treatment in Sputum of iraqi Patients with Pulmonary Tuberculosis Alzubaidi Liqa K. A.1, Alyasiri Nisreen Sherif2,*, Mehdi Luma yousif3 1Department of Community Health Techniques, Mosul Technical Institute, Northern Technical University, Mosul, Iraq 2Department of Nursing, AL-Suwaira Technical Institute 3Department of Medical Laboratory Technologies, College of Health and Medical Technology, Middle Technical University, Baghdad, Iraq *Corresponding Author: Nisreen Sherif Alyasiri, Department of Nursing, AL-Suwaira Technical Institute, Middle Technical University, Baghdad, Iraq, Email: dr-nisreensherif@mtu.edu.iq
Online published on 13 November, 2019. Abstract The role of IL-2 as a biomarker for tuberculosis disease has been assessed. Lung infection with Mycobacterium tuberculosis induce T cell responses which is mainly regulated by interleukin-2 (IL-2). recombinant human (rhIL-2) was administered with adjunctive immunotherapy to 30 patients diagnosed with primary tuberculosis (PTB), IL-2 level was observed in sputa at different intervals during treatment and at the mean time it was microscopically examined for acid fast bacilli (AFB). Thirty patients with latent tuberculosis after treatment (LTBat) in whom sputum production was successfully induced were also included. Placebo controlled trial patients were accredited twice injections of IL-2 on daily basis or placebo for the first 30 days of treatment. Subjects were followed for six months. The levels of IL-2 were increased in all patients compared to the control. Raised IL-2 level among LTBat patients was age dependent. Conversely, decreased IL-2 levels occur at the age 37 years and above. Increased IL-2 level in sputum enhanced bacillary smear clearance of patients with tuberculosis. Top Keywords Tuberculosis, IL-2, immunotherapy, Sputum. Top |